title: [Leflunomide and TNF inhibitors. Experiences from precription recourse proceedings].
authors.affiliation: Ärztehaus am Walter-Schreiber-Platz, Rheumapraxis Steglitz, Bundesallee 104/105, 12161, Berlin, Deutschland. brandt.rheumatologie@arcor.de
authors.forename: J
authors.initials: J
authors.lastname: Brandt-Jürgens
mesh_terms: D000068879:Adalimumab; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use*; D018450:Disease Progression; D016527:Drug Costs / Q000331:legislation & jurisprudence; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine / Q000331:legislation & jurisprudence; D005104:Expert Testimony / Q000331:legislation & jurisprudence; D005260:Female; D006801:Humans; D019458:Insurance Coverage / Q000191:economics* / Q000331:legislation & jurisprudence*; D007356:Insurance, Pharmaceutical Services / Q000191:economics / Q000331:legislation & jurisprudence; D007555:Isoxazoles / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D000077339:Leflunomide; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009313:National Health Programs / Q000191:economics* / Q000331:legislation & jurisprudence*; D056687:Off-Label Use / Q000191:economics* / Q000331:legislation & jurisprudence*; D011239:Prednisolone / Q000191:economics / Q000627:therapeutic use; D000079424:Tumor Necrosis Factor Inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007555:Isoxazoles; D000079424:Tumor Necrosis Factor Inhibitors; D011239:Prednisolone; D000068879:Adalimumab; D000077339:Leflunomide; D008727:Methotrexate